Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2020 February;64(1) > Journal of Neurosurgical Sciences 2020 February;64(1):37-43

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2020 February;64(1):37-43

DOI: 10.23736/S0390-5616.16.03745-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

LINAC-based radiosurgery for melanoma, sarcoma and renal cell carcinoma brain metastases

Ernesto MARANZANO 1 , Michelina CASALE 1, Rossella RISPOLI 1, 2, Fabio TRIPPA 1, Lorena DRAGHINI 1, Fabio ARCIDIACONO 1, Sandro CARLETTI 1, 2, Paola ANSELMO 1

1 Radiotherapy Oncology Center, S. Maria Hospital, Terni, Italy; 2 Neurosurgery Center, S. Maria Hospital, Terni, Italy


PDF


BACKGROUND: The aim of this study was to report response, overall survival (OS) and toxicity in patients with radioresistant brain metastases (BM) treated with stereotactic radiosurgery (SRS).
METHODS: Patients with renal cell carcinoma, melanoma and sarcoma with one to four brain metastases received SRS without whole brain radiotherapy.
RESULTS: Fifty patients with 77 BM were treated. 46 (92%) patients with 71 BM were evaluable. Median follow-up was 67 months and median OS 11.8 months. At the time of analysis all patients had died. Brain control was conditioned by response to SRS (P<0.0001), while OS by histology (renal cell carcinoma versus melanoma and sarcoma) (P=0.04) and status of the tumour outside the brain (P=0.05). Treatment was well tolerated without more than grade 2 acute toxicity.
CONCLUSIONS: Treatment of BM from radioresistant tumors with SRS assures good brain control and OS with low toxicity. Our data suggest a better prognosis associated to renal cell carcinoma histology.


KEY WORDS: Neoplasm metastasis; Brain; Radiosurgery

top of page